What Do Gastroenterologists Think About Biosimilars?

The American Gastroenterological Association surveyed 180 of its members on biosimilars and biologics.


Medical theme: doctors are studying a medical report.

In late July, the American Gastroenterological Association released findings from a national survey of gastroenterologists on biosimilars and biologics. Biologics are used regularly for the treatment of inflammatory bowel disease (IBD), and biosimilars for the treatment of IBD, such as Remsima/Inflectra are globally on the rise.

This survey reveals that many gastroenterologists are concerned about the safety and efficacy of biosimilars and that some are still unfamiliar with the type of drug itself. 

Read More